Lauren Perley is a Researcher affiliated with the Maternal Fetal Medicine Unit at Yale School of Medicine. She is part of the Yale Hearts Moms initiative (Lipkind Lab) and contributes to research on maternal and child health. Her work focuses on pregnancy complications, placental biology, and public health interventions. She holds an academic appointment at Yale University and collaborates with leading researchers in obstetrics and gynecology. Primary Affiliation: Yale School of Medicine Department: Maternal Fetal Medicine Unit Lab: Yale Hearts Moms (Lipkind Lab) Research interests include gestational diabetes, preeclampsia, maternal mortality, and environmental exposures during pregnancy. Her recent studies address mycotoxin exposure monitoring, non-invasive prenatal testing, and postpartum cardiovascular screening strategies. She has published extensively in top journals like Environment International and Biology Of Sex Differences . Dr. Perley's work bridges clinical practice and translational research, aiming to improve maternal and fetal outcomes through innovative diagnostic methods and population health strategies.
Ahmadreza Rezaeian is a Postdoctoral Associate at Yale School of Medicine , holding dual MPH and MD degrees from Shahid Beheshti University of Medical Sciences . His research spans multiple disciplines including Urology , General Surgery , and Mesenchymal Stem Cell applications. Education : MPH, Shahid Beheshti University of Medical Sciences (2022) MD, Shahid Beheshti University of Medical Sciences (2022) Rezaeian specializes in animal disease models , exosome therapy , and molecular oncology with a focus on urological cancers. His 12 publications and 77 citations highlight his contributions to kidney tumor genetics , renal transplant infections , and COPD pharmacology . His work includes systematic reviews on pandemic management strategies and book chapters on liquid biopsy techniques in urogenital cancers. Recent projects explore exosome interactions in prostate and bladder cancer cell lines. Scientific Awards : 2nd Rank in Master of Public Health (2022) 1st Rank in Medical School (2022) MPH Scholarship (2020) Medical School Scholarship (2013) Contact ahmadreza.rezaeian@yale.edu for collaborations at Brady Memorial Laboratory , Yale School of Medicine.
Daohai Yu, PhD, MS is a Professor at the Lewis Katz School of Medicine at Temple University, affiliated with the Center for Biostatistics and Epidemiology. He specializes in biostatistics with a focus on clinical trials, epidemiological study designs, and statistical modeling. His research addresses challenges in biomarker studies, longitudinal data analysis, and missing data problems. Dr. Yu holds a PhD from the University of Michigan and an MS from Sun Yat-sen University. Education: PhD in Biostatistics, University of Michigan, 2000 MS in Probability & Statistics, Sun Yat-sen University, 1987 Research Interests: Dr. Yu’s work bridges statistical methodology and biomedical applications. He focuses on optimizing study designs, analyzing time-to-event data, and developing joint modeling techniques. His collaborations aim to advance evidence-based treatments for diseases like cancer and neurological disorders. Recent studies include investigating maternal hypothyroidism impacts and cancer immunotherapy adjuvants. Professional Roles: Past Treasurer, North Carolina Chapter of the American Statistical Association; NIH ASG Study Section member; ENAR and International Biometric Society member. Labs/Teams: Active in Temple’s Center for Biostatistics and Epidemiology, contributing to interdisciplinary research projects.
L van Duin, PhD, MSc, is a Visiting Assistant Professor in the Department of Clinical Psychology at the Erasmus School of Social and Behavioural Sciences, Erasmus University Rotterdam. Their work bridges clinical psychology with prenatal medicine and oncology, reflecting a unique interdisciplinary profile. The research interests of L van Duin span clinical psychology , fetal and maternal medicine , psychopathy , electrophysiology , and recovery-oriented addiction care . Their work combines neurocognitive assessment with clinical applications in high-risk populations, including pregnant women with cancer and young adults with psychopathic traits. The recent publications reveal a strong trend toward interdisciplinary clinical research , particularly in the application of non-invasive prenatal testing (NIPT) for detecting maternal malignancies and understanding fetal congenital abnormalities. Parallel work explores neurocognitive markers of psychopathy and recovery support in addiction services, indicating dual expertise in biomedical and psychosocial domains. L van Duin has contributed to impactful clinical guidelines and peer-reviewed research in journals such as The Lancet Regional Health - Europe and Biological Psychology . While no formal scientific awards are listed, the collaboration with the Dutch NIPT Consortium and publication in high-impact venues reflect recognition in the field. L van Duin has co-authored multiple research outputs, including articles and reports, often in collaborative teams. Though no direct advising or grant information is available, their involvement in multi-center studies suggests active participation in funded research projects. Their work with the Dutch NIPT Consortium and IVO Addiction Research Institute highlights engagement with both national health initiatives and specialized research centers. While no dedicated lab or team is explicitly mentioned, L van Duin collaborates extensively within networks focused on prenatal diagnostics, oncology, and psychological interventions, as evidenced by co-authorship and institutional affiliations.
Ruchi Mittal is a Senior Health Economist at the School of Public Health within the Faculty of Health and Medical Sciences at The University of Adelaide, working with Adelaide Health Technology Assessment (AHTA). Her research focuses on health economics, decision analytic modeling, and evidence-based medicine, with an emphasis on evaluating healthcare technologies and interventions. Her work includes assessments of genetic testing for conditions like Lynch syndrome, fertility preservation techniques (e.g., ovarian and semen cryopreservation), and imaging modalities such as PET/CT and cardiac MRI. Publications also span computational chemistry methodologies, including QSAR modeling for drug discovery. Key contributions include economic evaluations of medical technologies and policy-relevant analyses for bodies like MSAC. Her research bridges clinical decision-making and cost-effectiveness, addressing challenges in healthcare resource allocation. Publications highlight collaborations on genetic testing policies, fertility preservation strategies, and diagnostic imaging innovations. Her work supports evidence-based healthcare through rigorous health technology assessments and economic modeling.
Solveig Norheim Andersen is a scientific researcher affiliated with the Clinic for Internal Medicine and Laboratory Sciences at Akershus University Hospital and the Faculty of Medicine at the University of Oslo. She has been consistently active in medical research from the 1970s to the present, with a focus on gastrointestinal pathology and cancer biology. Her research interests are deeply rooted in molecular pathology , particularly in colorectal cancer , ulcerative colitis , and inflammatory bowel disease . She investigates key molecular markers such as K-ras mutations , p53 alterations , microsatellite instability , NUCKS1 , and HER2 signaling , often in the context of cancer progression and patient prognosis. Her work bridges clinical pathology with translational research, aiming to improve diagnostic accuracy and therapeutic strategies. The recent articles highlight a strong trend in oncology , surgical pathology , and molecular diagnostics , with increasing emphasis on biomarker validation , cancer staging refinement , and surveillance techniques in gastrointestinal diseases. Her publications span high-impact journals in gastroenterology, oncology, and molecular pathology, reflecting interdisciplinary collaboration and clinical relevance. She has collaborated extensively with leading researchers including Ole Petter Clausen, Paula De Angelis, Tone Løvig, and Torleiv Rognum, and has contributed to multicenter clinical trials in colorectal cancer. Her work in D3 mesenterectomy , lymph node micrometastases , and preoperative anatomical mapping has contributed to surgical oncology practices. Dr. Andersen has been involved in research groups such as the Pathology group at Ahus, indicating leadership and sustained engagement in laboratory-based and clinical research. While no formal awards or students are listed, her long publication history and senior authorship positions suggest mentorship and recognition within the field.
Gosia Srebniak is a researcher at Erasmus MC, affiliated with the Department of Clinical Genetics within the Erasmus School of Medicine. Her work focuses on advancing prenatal genetic diagnostics through non-invasive methods and large-scale genomic analysis. Her primary research interests include Non-Invasive Prenatal Testing (NIPT) , exome sequencing , cell-free DNA analysis , mosaicism , and chromosomal aberrations . She plays a key role in evaluating and implementing national prenatal screening programs, particularly through the TRIDENT studies, aiming to improve diagnostic accuracy and clinical decision-making. The recent publications highlight a strong trend in prenatal genetic screening , diagnostic yield optimization , and clinical translation of genomic technologies . Her research bridges molecular genetics with obstetric practice, contributing to evidence-based guidelines in prenatal care. Scientific Contributions: Key contributor to national NIPT implementation studies Research on confined placental mosaicism and pregnancy outcomes High-impact studies on prenatal exome sequencing in fetuses with anomalies Investigations into nuchal translucency thresholds and genetic testing Exploration of cfDNA testing in pregnancy-associated cancer Dr. Srebniak collaborates extensively across multicenter consortia and has contributed to over 70 research outputs. While formal advising roles are not mentioned, her work supports clinical training and policy development in prenatal genetics. She is involved in large cohort studies and national health initiatives, reflecting significant grant-supported research activity. She is part of active research networks in clinical genetics and prenatal diagnosis, contributing to both Dutch and international collaborations in genetic screening and fetal medicine.
Dr. Marieke Joosten is a researcher in the Department of Clinical Genetics at Erasmus MC, a leading academic medical center in the Netherlands. Her work is centered on clinical and molecular genetics, with a strong focus on prenatal diagnostics and genomic technologies. Her research interests include: Exome sequencing in prenatal diagnosis Cell-free DNA analysis Chromosomal aberrations and mosaicism Karyotyping Genetic counseling Her recent publications highlight a consistent focus on improving diagnostic accuracy in prenatal settings, particularly through advanced genomic techniques. She frequently collaborates with multidisciplinary teams on studies involving prenatal exome sequencing, non-invasive prenatal testing (NIPT), and the detection of maternal malignancies through fetal screening. Her work bridges clinical practice and genetic research, contributing significantly to patient management protocols. Notable scientific contributions include research on confined placental mosaicism, high-yield prenatal exome sequencing, and clinical guidelines for managing abnormal NIPT results suggestive of maternal cancer. These have been published in top journals such as The Journal of Experimental Medicine , Prenatal Diagnosis , and The Lancet Regional Health - Europe . She actively contributes to public engagement through press coverage of her research and is part of the Dutch NIPT Consortium, reflecting her role in national collaborative efforts. While no formal advising or grant information is provided, her extensive publication record and media presence underscore her active and influential role in clinical genetics research.
Michael Giacomelli is a Professor specializing in biomedical imaging technologies. He previously worked as a research scientist at MIT's Research Lab of Electronics, collaborating with Beth Israel Deaconess Medical Center and the VA Medical Center in Boston. His research focuses on multiphoton and fluorescence imaging for clinical and surgical applications, emphasizing real-time pathology assessment. He holds a PhD in Biomedical Engineering from Duke University and dual B.S. degrees in Computer Engineering and Computer Science from the University of Arizona. Research interests include multiphoton microscopy, high-throughput imaging systems, and medical imaging instrumentation. The Giacomelli Lab designs custom microscopes and algorithms for clinical use, prioritizing usability by non-engineers. Recent work emphasizes silicon photomultiplier arrays and piston-based specimen holders to improve imaging speed and accuracy in surgical settings. Key advancements include real-time margin assessment during Mohs surgery and rapid biopsy analysis. His innovations bridge engineering and medicine, with applications in oncology, dermatology, and gastroenterology. The lab collaborates extensively with clinical partners to translate technologies into usable diagnostic tools. Publications from 2024-2025 highlight improvements in imaging speed, spectral throughput, and clinical validation of imaging systems. Current work focuses on low-cost solutions for tissue processing and enhancing detector sensitivity for wide-scale clinical adoption.
Professor Jyrki Vuorinen serves as the Dean of the Faculty of Information Technology and Communication Sciences at Tampere University. His research focuses on advanced materials science, with expertise in polymer composites, nanotechnology, and biomedical materials. He has contributed significantly to studies on material durability, interfacial adhesion, and energy-efficient material formulations. His work bridges fundamental material science with industrial applications, particularly in rubber composites, nanodiamond-enhanced materials, and biocompatible nanolaminates. Recent projects include developing non-invasive cancer detection methods using urine DNA panels and optimizing microwave-assisted surface treatments for aramid fibers. He holds a leadership role in advancing interdisciplinary research at Tampere University. Research interests span from polymer science and surface engineering to biomedical applications of materials. Key themes include enhancing material mechanical properties through nanomaterial integration, studying environmental effects on material durability, and advancing sustainable recycling of multilayer plastics. His work often addresses real-world challenges in corrosion resistance, energy dissipation in elastomers, and antibacterial polymer fibers for medical textiles. His publications highlight trends in composite material innovation, with emphasis on nanocomposite formulations, dielectric material optimization, and interface modification techniques. Articles from 2018–2023 reflect a focus on translating laboratory findings into industrial solutions, such as improving rubber-metal adhesion and developing cost-effective diagnostic tools. No scientific awards or grants are explicitly listed in the provided texts, though his extensive publication record suggests significant academic contributions. His advising activities are not detailed here, but his research team likely focuses on materials science and engineering disciplines. He contributes to maintaining Tampere University’s reputation in cutting-edge materials research and interdisciplinary education.
Dr. Jeremiah Gassensmith is an Associate Professor in Chemistry & Biochemistry at the University of Texas at Dallas (UTD), affiliated with the School of Natural Sciences and Mathematics. He holds additional roles as Affiliated Faculty in the Department of Biomedical Engineering and Associate Member of the Simmons Comprehensive Cancer Center (UT Southwestern). His research focuses on nanomedicine, stimuli-responsive biomaterials, and molecular imaging, particularly leveraging virus-like particles and metal-organic frameworks (MOFs) for vaccine development, targeted therapy, and non-invasive diagnostics. Professional preparation includes a B.S. (Indiana University, 2003), Ph.D. (University of Notre Dame, 2009), and postdoctoral training in nanotechnology (Northwestern University, 2013). Key research areas include stabilizing vaccines via MOF encapsulation, developing light-responsive virus-based drug carriers, and creating organic radical contrast agents for MRI. He is recognized for innovations in room-temperature-stable vaccines, photothermal therapy, and biocompatible imaging agents. His work has been honored with awards such as the Alexander von Humboldt Fellowship (2024), Royal Society of Chemistry Fellowship (2022), and NSF Career Award (2017). He mentors a diverse team of researchers, including graduate and undergraduate students, and contributes to scientific leadership as an Associate Editor of Chemical Engineering Journal . Ongoing projects aim to translate lab discoveries into clinical tools for addressing global health challenges like vaccine accessibility and antibiotic-resistant infections.
Antonio Gomez Tato is a Professor at the Department of Mathematics , Faculty of Mathematics , University of Santiago de Compostela. He is affiliated with the Galician Mathematical Research and Technology Center (CITMAga) and the Mathematics Research Group in Mathematics , with a focus on BioMatDataAnalysis (data analysis and mathematics in life sciences). His primary research area is Geometry and Topology . Email: antonio.gomez.tato@usc.es Research Interests: Dr. Gomez Tato’s work bridges pure mathematics and interdisciplinary applications. His formal academic area is Geometry and Topology, but his publications span proteomics, epigenetics, aquaculture genetics, and forensic DNA phenotyping. Key themes include: Mathematical modeling in biological systems Proteomic and transcriptomic analysis of cancer and marine species DNA methylation-based age and ancestry prediction Development of non-invasive diagnostic tools (e.g., WomEC for endometrial cancer) Genomic resources for flatfish species Publication Trends: Recent work emphasizes biomarker discovery for cancer diagnostics (2024–2025), forensic genetics (2024–2023), and aquaculture genomics (2016–2021). Earlier papers delve into DNA methylation, circulating tumor cells, and immune response gene expression. Despite no explicit awards listed, his extensive publication record across disciplines highlights significant contributions to mathematical biology and clinical/translational research.
Kiaran P. McGee, Ph.D. is a Professor of Medical Physics and holds an academic rank of Assistant Professor of Biomedical Engineering at Mayo Clinic. His primary appointment is as a Consultant in the Department of Radiology at Mayo Clinic, Rochester, Minnesota. He is Director of the Imaging Biomarker Discovery Program at the Center for Individualized Medicine. Education: Ph.D. in Biomedical Imaging (Mayo Clinic Graduate School) Ph.D. in Biophysics/Biomedical Engineering (Mayo Graduate School) MS in Medical Physics (University of Manitoba) BS in Applied Science (University of Technology, Sydney) Research Focus: Dr. McGee specializes in advancing MRI and MRE (Magnetic Resonance Elastography) techniques for diagnosing diseases such as lung fibrosis, heart conditions, and cancer. His work emphasizes non-invasive imaging of tissue mechanical properties to improve early disease detection and therapy monitoring. Key projects include: Development of MRE for parenchymal lung diseases MRI techniques for radiation therapy planning Biomarkers of therapy response in cancer Publications & Awards: Dr. McGee has authored over 100 peer-reviewed articles and holds awards such as the 2016 Distinguished Reviewer Awards and the Minnesota Teckne Finalist (2015). He contributed to the NIH-funded Regional Assessment of the Lung Using MRE project (2009–2010). Professional Roles: Chair of AAPM Task Group on MR Biomarkers in Radiation Oncology Member of multiple professional committees (AAPM, RSNA) Editorial board member of Medical Physics Journal Labs & Collaborations: He leads the Imaging Biomarker Discovery Program and collaborates with institutions like Beijing Anzhen Hospital and Mayo-Illinois Alliance.
Daniel Lundqvist is Professor of Neuroimaging at Karolinska Institutet, appointed to this position effective November 1, 2024. He is affiliated with the Department of Clinical Neuroscience within the Faculty of Medicine and serves as Director of the Centre for Imaging Research (CIR) at BioClinicum. Additionally, he leads the Swedish node of the EU project "TEF-Health - Testing and Experimentation Facilities for Health AI and Robotics" and is the Scientific Director of NatMEG - the National Facility for Magnetoencephalography. His Multimodal Brain Imaging research group investigates how brain structure, function, and neurochemistry shape human consciousness, perception, decisions, and actions. Lundqvist earned his Doctor of Philosophy from Karolinska Institutet's Department of Clinical Neuroscience in 2003 and was awarded Docent (Associate Professor equivalent) status in 2016. His academic progression includes Senior Research Specialist (2021-2024) before his promotion to full Professor of Neuroimaging. Dr. Lundqvist's research centers on advancing magnetoencephalography (MEG) and on-scalp MEG technologies to elucidate neuronal brain activity. His work bridges cognitive, affective, and clinical neuroscience with a focus on both fundamental brain mechanisms and clinical applications. He combines two complementary approaches: one focused on his own research projects investigating the brain-mind relationship, and another aimed at promoting the imaging ecosystem across Karolinska Institutet, Karolinska University Hospital, and Europe. His research spans epilepsy, Parkinson's disease, emotion processing, social neuroscience, and the development of novel neuroimaging methodologies, with increasing integration of AI and computational approaches in recent years. His recent publications demonstrate a strong focus on advancing MEG technology for clinical applications, particularly on-scalp MEG. His work spans diverse neurological and psychiatric conditions while developing innovative imaging methodologies. A significant thread through his research is the application of advanced imaging techniques to understand both healthy brain function and neurological disorders, with particular emphasis on Parkinson's disease, epilepsy, and emotion processing. The cognitive neuropsychiatry of prediction systems in psychosis (Swedish Research Council, 2024-2026) CAPSI - Cancer related major depression treated with a single dose of psilocybin (Swedish Research Council, 2023-2026) TEF HEALTH (VINNOVA, 2022-2027) Finding a cognitive needle in a neural haystack (Swedish Research Council, 2022-2024) HD-MEG: High-definition neuroimaging for understanding the brain in health & disease (Swedish Research Council, 2022-2025) NatMEG: On-Scalp MEG Platform (Swedish Research Council, 2021-2025) Lundqvist has supervised doctoral and master students as part of his extensive teaching contributions across neuroscience education and brain imaging methods. His leadership extends to directing major research facilities and collaborative projects, including his role as National Node lead for TEF-HEALTH, which received over SEK 100 million in EU funding. His Multimodal Brain Imaging group forms part of the Brain & Mind academic environment that brings together cognitive neuroscience researchers using various brain imaging techniques to understand brain function in health and disease.
Ana Maria Balseiro Morales is a Professor at the University of León, affiliated with the Faculty of Veterinary Medicine's Animal Health department. She specializes in veterinary pathology, wildlife health, and infectious disease epidemiology. Doctoral graduate from the University of León (2004), her thesis focused on Bovine paratuberculosis assessment of cross-reactions with the tuberculin test, evaluation of diagnostic techniques and prevalence in Asturias . She has supervised multiple research projects through her leadership in the PASAFA Pathology and Animal Health in Wildlife and SANPATRUM Health and Pathology of Ruminants research groups. Research Focus: Paratuberculosis biomarkers, tuberculosis epidemiology, wildlife-livestock interface diseases, zoonotic surveillance, and ecological health interactions Key Techniques: Immunohistochemistry, proteomic profiling, molecular epidemiology, and non-invasive pathogen monitoring Conservation Impact: Studying emerging threats to endangered species like Cantabrian brown bears and Cantabrian capercaillie Her recent publications (2024-2025) demonstrate interdisciplinary work across veterinary medicine, wildlife conservation, and public health. The research spans tuberculosis dynamics in multi-host systems (7 articles), parasitology (4 articles), zoonotic disease monitoring (5 articles), and novel diagnostic approaches (4 articles). Specific subfields include mycobacterial infections, cross-protective immunity, parasite ecology, and conservation pathology. As part of the Faculty of Veterinary Medicine, she contributes to both research and education, particularly evident from her work on virtual microscopy for histology teaching during post-pandemic distance learning contexts.
